

Numbering Positions in HIV Relative to HXB2CG

Bette T. Korber,¹ Brian T. Foley,¹ Carla L. Kuiken,¹ Satish K. Pillai,¹
and Joseph G. Sodroski²

¹ *Theoretical Biology and Biophysics, Group T-10, MS K710, Los Alamos National Laboratory, Los Alamos, NM 87545;*

² *Howard Hughes Medical Institute, Columbia University, New York, NY 10032*

In this section we present a simple numbering scheme to facilitate the identification of the position number or precise location of interest in HIV DNA or proteins.

Inconsistent and inaccurate numbering of locations in HIV DNA and protein sequences is a serious problem in the HIV literature. Therefore we decided to provide a practical guide to help circumvent these problems in the future, and to attempt to bring a common language into discussions in the field. We present a clearly numbered set of proteins, and the full length genome, for HIV HXB2, GenBank accession number K03455. HIV HXB2 is also known as: HXB2, for HXB clone 2; HXB2R, in the Los Alamos HIV database, with the R for revised, as it was slightly revised relative to the original HXB2 sequence; and HXB2CG in GenBank, for HXB2 complete genome. Our web site has an interactive program to further facilitate obtaining position numbers relative to HXB2CG (<http://hiv-web.lanl.gov/NUM-HXB2/HXB2.MAIN.html>).

HXB2 was selected as the prototype, because this virus is the most commonly used reference strain for many different kinds of functional studies. Importantly, all of the envelope structural data published to date translates residue numbers into the HXB2 numbering scheme. Now that a core HIV-1 gp120 structure is solved (for review, see Wyatt et al, this compendium), it has become apparent that conservation in core sequences, especially in hydrophobic interior domains, exists to preserve similar folding in gp120 variants. As the envelope protein is riddled with insertions and deletions, it is particularly problematic for numbering. The current system, of sequentially numbering proteins from any strain, lacks a common way to refer to specific locations in a protein. We propose the following system to circumvent this problem:

1) *Case of insertion in sequence relative to HXB2CG.* Use residue number/alphabet (e.g., 131a, 131b, 131c, etc.) to refer to residues in variable regions that are “extra” compared to what HXB2 has. A similar scheme has

been used for immunoglobulin complementarity-determining region (CDR) loops (see Lucas et al., *J Immunol* 1998 **161**:3776–80 (1998) for an example).

Example: If the region under study is LLLTRDGGSNRSEPEVEIFRP of ENVB, gp120,

452		465		470	HXB2 amino acid position from start of gp160
LLLTRDGGNSNNEE--EIFRP		LLLTRDGGNSNNEE--EIFRP		HXB2	
LLLTRDGGSNRSEPEVEIFRP		LLLTRDGGSNRSEPEVEIFRP		ENVB	

one could refer to it as corresponding to HXB2 gp160 position numbers 452–470 with a two base insertion (465a = E and 465b = V)

2) *Case of deletion in sequence relative to HXB2.* Indicate the deleted residues.

Example: If the region under study is LLLTRDGGNN of 92RW020.5,

452		463	HXB2 amino acid position from start of gp120
LLLTRDGGNSNN		HXB2	
LLLTRDGG..NN		92RW020.5	

one refers to it as corresponding to HXB2 gp160 position numbers 452–463 with a two base deletion at positions 460–461. We suggest using the annotation 452–463(del 460-461) to make this explicit.

The sequential numbering relative to either 92RW020.5 or ENVB could also be provided in the above two examples, but the HXB2 numbering should also be provided as a reference.

The benefit of this numbering strategy is that, for example, aspartate 368, which is involved in CD4 binding, or gp160 368 D, means the same thing to everyone working on envelope glycoproteins, regardless of the reference strain they used in their particular studies.

Also, when working with a short functional domain, epitope, or primer, researchers should publish the precise amino acid or nucleotide string that they are working with, as well as the HXB2 numbered positions, to ensure that there is no confusion (for example, write out ENVB LLLTRDGGSNRSEPEVEIFRP as well as give the boundary position numbers).

HXB2 Amino Acid Sequence Numbering:

Gag Pr55 Gag precursor (Assemblin)

MGARASVLSG GELDRWEKIR LPPGGKKKKKY LKHIVWASRE LERFAVNPGL LETSEGCRQI LGQLQPSLQI GSEELRSLYN TVATLYCVHQ RIEIKDTKEA 100
 LDKTIEEQNK SKKKAQQAAD DTGHSNQVSQ NYPIVQNIQG QMVHQAI SPR TLNAWKVV E EKAFSPVIV MFSALSEGAT PDIINTMLNT VGGHQADAMQ 200
 LKETINEEAA EMDRVHPVHA GPLADGQMR E PRGSDIAGTT STLQEQIGMM TNNPPIVGE IYKRWITLGL NKIYRMYSPT SILDIRQPK EPRRDYVDRF 300
 YKTLAEQAS QEVKNWMTET LLYQANPDC KTIILKALGPA ATLEEMTAC QGVGPGHKA RVLAEAMSQV TNSATIMQR GNFRNQRKIV KCFNCGKEGH 400
 TARNCRAPRK KGCWCGKEG HQMKDCTERQ ANFLGKIWPS YKGRPGNFLQ SRPEPTAPPE ESFRSGVETT TPPQKQEPID KEIYPLTSLR SLFGNDPSSQ 500

Gag p17 Matrix

MGARASVLSG GELDRWEKIR LPPGGKKKKKY LKHIVWASRE LERFAVNPGL LETSEGCRQI LGQLQPSLQI GSEELRSLYN TVATLYCVHQ RIEIKDTKEA 100
 LDKTIEEQNK SKKKAQQAAD DTGHSNQVSQ NY 132

Gag p24 Capsid

PIVQNIQGM VHQAISPRTL NAMWKVVEEK AFSPEVIMPF SALSEGATPQ DLNTMILNTYG GHQAAMQMLK ETINEEAEM DRVHPVHAGP IAPGQMRER 100
 GSDIAGTTST LQEQIGMNTN NPIIPVGEIY KRWIILGLNK IVRMYSPTS I IDIRQPKRP FRDYVDRFYK TLRAEQASQE VKMWTETLL VQANPPDCKT 200
 ILKALGPAAT LEMWTAQCG VGGPGHKARV L 231

Gag p2

AEAMSQVTNS ATIM 14

Gag p7 Nucleocapsid

MQRGNFRNQR KIYKCFNCGK EGHRTARNCR A PRKKGWCKG KEGHQMKDCT ERQAN 55

Gag p1

FLGKIWPSYK GRPGNF 16

Gag p6

LQSRPEPTAP PESSFRSGVE TTPPPQKQEP IDKELYPLTS LRSLFGNDPS SQ 52

Pol polyprotein:

FFREDLAFIQ GKAREFSSSEQ TRANSPTRRE LQVWGRDNNS PSEAGADRQG TVSFNFPOVY IMQRPLVYTIK IGGQLKEALL DTGADDTVLE EMSLPGRWKP 100
 KMIIGGEGFI KVRQYDILI EICGHKAIGT VLVGPTPVNI IGRNLLTQIG CTINFPISPI ETVPVKPKPG MDGPKKQWP LTFEKKIKALV EICTEMEKEG 200
 KISKIGEPNG YNTPVFAIKK KSTGRKRLV DFERLNKRTQ DFWEVQLGIP HPAGLKKRKS RHTLVKGDY FSVPLDEDER KYTAFITPSI NNETPGIRYQ 300
 YNVPDQWKP SPAIFQSSMT KLEPFPRKQV PDIVITYQYMD DLYVGSIDLEI GQHRKTFIEEL RQHLRKGILT TPDKKHQQEP PFLMMGYELH PDKWTVQPIV 400
 LPEKDSWTVN DIQKLVGKLN WASQIYRPIK VRQKLVQKLG TKALTEVYIPL TEEAELELAE NREILKEPVH GVVYDPSKDL IAEIQKQGG QWTVQIYQEP 500
 FKNLKTGKYA RMRGAHTNDV KQLEAVOKI TTESIVIWGK TPKFKLPIDQ ETWETWWTY WOATWIPEME FVNTPELVKL WYOLEKEPIV GAETFFYVDA 600
 ANRETKLGKA GYVTNRGRQK VVTLTDTTNQ KTELQAIYLA LQDSGLEVNI VTDSQYALGI IQAQPDQSES ELVNDIIEQL IKKEKYYLAW VPAHKGIGGN 700
 EQVDKLVASAG IRKVLFLDGI DKAODEHEKY HSNWRAMASD FNLPPVYAKE IVASCDKQL KGEAMHQVD CSPGIMQLDC THLEGKVILV AVHVASGYIE 800
 AEVIPAETGQ ETAYFLKLA GRWPVKTIHT DNGSNFTGAT VRAACMWAGI KOEFGIPYNP QSQGVVBSMN KELKTIIGQV RDQAHLKTA VQMAVFIHNF 900
 KRKGGIGGYS AGERIVDIIA TDIQTKELOK QITKIQNFVY YRDSRNPLM KGPALKLWKG EGAVVIQDNS DIKVVPRRKA KIIRDYQKQV AGDDCVASRQ 1000
 DED 1003

Pol p10 Protease

PQVTLWQRPV VTIKIGGQLK EALLDTGAD TYLEEMSLPG RWKPKMIGGI GGFIKVRQYD QILIEIGCHK AIGTVLVGPT PVNIIGRNL TQIGCTLNF 99

Pol p66 Reverse Transcriptase (RT/RNase)

PISPLETVPV KLRGMDGPK VKQWPLTEEK IKALVEICTE MEKEGKISKI GPENPVNTPV FAIKKKDSTK WRKLVDFREL NKRTODFWEV QLGIPHPAGL 100
 KKKKSTVLD VGDYFYSVPL DEDFRKYTAF TIPSINNETP GIRYQYVNLV QGWKSPAIY QSSMTKLEP FRKQMPDIVI YQYMDLIVG SDLEIGQHRV 200
 KIEELRQHLL RWGLITPPDKK HQKEPFLWM GYELHPDKWT VQPIVLPKED SWTVNDIQKL VGKLNWASQI YPGIKVRQLC KILRGTKALT EVIDLTEAE 300
 LELAENREIL KEPVHGVVYD PSKDLIAEIQ KQGQGWTVYQ IYQEPFKNLK TGKYARMRGA HTNDVKQLTE AVQKITTESI VIMGKTPPKF LPIQKETWET 400
 WMTWYQATW IPEWEFVNTP PLYKLMYQLE KEPIVGAETP 440
 YALGI IQAQP DQSESELVNQ IIEQLIKKEK VYLAWVPAHK 560

Pol p51 RT

PISPLETVPV KLRGMDGPK VKQWPLTEEK IKALVEICTE MEKEGKISKI GPENPVNTPV FAIKKKDSTK WRKLVDFREL NKRTODFWEV QLGIPHPAGL 100
 KKKKSTVLD VGDYFYSVPL DEDFRKYTAF TIPSINNETP GIRYQYVNLV QGWKSPAIY QSSMTKLEP FRKQMPDIVI YQYMDLIVG SDLEIGQHRV 200
 KIEELRQHLL RWGLITPPDKK HQKEPFLWM GYELHPDKWT VQPIVLPKED SWTVNDIQKL VGKLNWASQI YPGIKVRQLC KILRGTKALT EVIDLTEAE 300
 LELAENREIL KEPVHGVVYD PSKDLIAEIQ KQGQGWTVYQ IYQEPFKNLK TGKYARMRGA HTNDVKQLTE AVQKITTESI VIMGKTPPKF LPIQKETWET 400
 WMTWYQATW IPEWEFVNTP PLYKLMYQLE KEPIVGAETP 440

Pol p15 RNase

YVDGANRET KLGKAGYVTN RGRQKVTLT DTTNOKTELO AIYLLAQDSG LEVNIYVDSQ YALGI IQAQP DQSESELVNQ IIEQLIKKEK VYLAWVPAHK 100
 GIGNEQVDK LVSAGIRKVL 120

Pol p31 Integrase

FLDGLDKAQD EHEKYHSNWR AMASDFNLPP VVAKEIVASC DKCQLKGEAM HGQVDCSPGI WQLDCTHLEG KVILYAVHVA SGYTEAEVIP AETGQETAYF 100
 LLKLAGRWPV KTIHTDNGSN FTGATVRAAC MWAGIKQEFEG IPYNPQSQGV VESMNKELKK IIGQVRQDAE HLKTAVQMAV FFINHFKRKG IGGVSAGERI 200
 VDIATDIQT KELQKQITKI QNFRVYYRDS RNPIMKGPAP LIMGEGAVV IQDNSDIKVV PRRAKAIRD YKQMAGDDC VASRQDED 288

Numbering Positions in HIV

Vif

MENRWQVMIV WQVDRMRIRT WKSLVKHHMY VSGKARGWFY RHHYESPHPR ISSEVHIDLG DARLVIITTYW GLHTGERDWH LGQGVSIEMR KRRYSTQVDP 100
 ELADQILHLY YFDGFSDSA I RKAIIIGHIVS PRCEYQAGHN KVGSLQYLAL AALITPKKIK PPLPSVTKLT EDRWNKPQKT KHRGSHSTMN GH 192

Vpr

MEQAEEDQGP QREPHNEWTL ELLEELKNEA VRHFPRIMLH GLGQHIYETY GDTWAGVEAI IRIIQQLFI HFRIGGRHSR IGVTRQRRAR NGASRS 96
 HXB2 frameshift \ /

Tat (premature HXB2 stop codon indicated by \$)

MEPVDRLEP WKHPGSSQPKT ACTNICYCKKC CFHCQVCFIT KALGISYGRK KRRQRRRAHQ NSQTHQASLS KQPTSQPRGD PTGPKK\$KKK VERETETDPF 100
 D | Primary splice site 101

Rev

MAGRSGDSDE ELIRTVRLIK LLYQSNPPPN PEGTRQARRN RRRWRERQR QIHSISERIL GTYLGSAEP VPLQLPPLER LTLDCNEDCG TSGTQGVGSP 100
 QIIVESPTVL ESGTKE | Primary splice site 116

Vpu (defective start codon)

TQPRIVAVI ALVVAIIIIAI VVWSIVIIIEY RKLIRQKID RLIDRLIERA EDSGNESEGE ISALVENGYE MGHHADWDVD DL 82

Envelope (Env) gp160

Env signal peptide |

MRVKEKYQHL WRMGWRWGTM LIGMLMICSA TEKLWVTVYV GVPVWKEATT TLFCA\$ADAKA YDTEVHNWVA THACVPTDPN PQEVVLVNVV ENFNMMKNDM 100
 VEQMHEDIIS LMDQSLKPCV KLTPLCVSLK CTDLKNDTNT NSSSGRMIME KGEIKNCSFN ISTSIRKVVQ KEYAFYKLD IIPIDNDTTS YKLTSCNTSV 200
 ITQACPKVSF EPIPIHYCAP AGFAIILKCNN KTFNGTGPCI NVSTVQCTHG IRPVVSTQLL INGSIAEEV VIRSVNFTDN AKTIIVQINT SVEINCTRPN 300
 NNTRRIRIQ RGPGRAFVTI KIGNMRQAH CNISRAKWN TLKQIASKLR EQFGNKTII FKQSSGGDPE IVTSHFNCGG EPHYCNSTQL FNSTWFNSTW 400
 STEG\$NNT\$EG SDTITLPCRI KQILINWQKV GKAMYAPPIS QQIRCSSNIT GLLLTRDGGN SNNESEIFRP GGGDMRDNWR SELYK\$K\$VVK IEPDLGVAPTK 500
 > gp41 start

AKRRVVQREK RAVGIGALFL GFLGAAGSTM GAASMTLTVQ ARQLL\$GIVQ QQNNILRAIE AQQHLIQLTV WGIKQLQARI LAVERYLKDO QLLGIWGC\$G 600
 KLICTTAVPW NASWSNKSLE QIWNHTT\$WME WDREINN\$YTS LIHSLIEESQ NOQEKNEQEL LELDKWASLW NWFNITNWLW YIKL\$FIMIVG GLVGLRIVFA 700
 VLSIVNVRQ GY\$PLSFQTH LPTPRGPPDRP EGIEE\$GGER DRDRSIRLVN G\$LALIMDDL RSLCLF\$YIHR LRDLLIVTR IVELLGRRW EALKY\$W\$NLL 800
 QYWSQELKNS AV\$LLNATAI AVAEGTDRVI EVVQ\$ACRAI RHIPRIRIQ LERILL 856

Nef (premature HXB2 stop codon indicated by \$)

MGKWSKSSV IGWPTVRE\$RM R\$AEPADRV GAASRDLEKH GAITSSNTAA TNAACAWLEA Q\$EEFVGF\$V TPQVPLRPMT YKA\$VDL\$HF LKEKGLLEGL 100
 IHSQRQDIL DLWITYHTQY FPD\$QNTYTPG P\$VRYPLTFG WCYKLVPEP DKIEFAN\$E NTSILH\$VSL HGM\$DPEREV LEMRFDSRLA FHHVARELHP 200
 EYFKNC 206

HXB2 Nucleotide Sequence Numbering:

```

> 5' LTR U3 region start
tggaaaggct aattcactcc caaagaagac aagatatacct tgatctgtgg atctaccaca cacaaagcta cttccctgat tagcagaact acacaccagg 100
gccagggata agatataccac tgaaccttgg atygtgttac aagctagttac cagttgagcc agagaagtta gaagaagcca accaaaggaga gaaccaccagc 200
ttgttacacc ctgtgagcct gcatggaatg gatgaccagg agaagaagtt gttagagtgg aggtltgaca gccgccttagc atttcatcac atgagccagg 300
agctygalcc ggaagtacttc aagaactgct gaacatcgagc ttgctacaag ggaacttccg ctggggaactl tccagggagg cgtggcctgg gccggactgg 400

                    5' LTR U3 region end \ / 5' LTR R repeat start
ggagtggcga gccctcagat cctgcatata agcagctgct ttttgcctgt actggtctc tctggttaga ccagatcctga gcctgggagc tctcttgcta 500

                    5' LTR R          5' LTR U5
                    repeat end \ / region start
actaagggaac ccaactgtta agcctcaata aagcttgccct tgaigtcttc aagtagtgtg tgcctgtctg ttgtgtgact ctggttaacta gagatccctc 600

                    5' LTR U5 region end <
agacccttlt agtcaagtgtg gaaatctct agcagtgycg cccgaacagg gacctyaaag cgaaggggaa accagaggag ctctctcgac gcaggactcg 700

                    > Gag p17 start
gcttctgtaa gccgcgaccgg caaagaagcga gggggcggcga ctggtgagta cgcctaaaat ttgactagc ggaagcctaga aggaaagaga tgggtgcgag 800
agcgtcacgta ttaagcgggg gagaattaga tccatgggaa aaaattcggf taagrgccagg gggaagaagaa aatataaat taaaacatat agtataggca 900
agcaggggag tagaacgatt cgcagttaat cctggcctgt tagaaccatc agaagctgtg agacaatatc tgggacagct accaacatcc ctccagacag 1000
gatcagaaga acttagatca ttatataata cagtagcaac cctctatgtg gtgcatcaaa gगतगगत aaaaagacacc aaggaagctt tagacaagat 1100

                    Gag p17 end \ / Gag p24 start
agaggaagag caaaaacaaa gtaagaaaaa agcacacagcaa gcagcagctg acacagggaca cagcaatcag gtcagccaaa atlacctat agtgcagaac 1200
atccaggggc aaatggtaca tcaaggcata tcaacctaga cttaaatgc atygttaaaa gtagtagaag agaagctt cagccagaa gttgatacca 1300
tgtttcagc atlatcagaa ggaagccacc cacaagattt aaacaccatg ctaaacacag tgggggggaca tcaagcagcc atgcaaatgt taaaagagac 1400
catcaatgag gaagctgcag aatgggatag agtgcattca gtgcatgcag ggcctatgac accagggcag atgagaagac caaggggaag taccatagca 1500
ggaactacta gtacccttca ggaacaataa gगतगगत caaataatcc acctatcca gtaagrgaaa ttataaaaag atgataatc ctgggattaa 1600
ataaaatagt aagaaatgat agccctacca gcatcttggg cataagaaca ggaaccaaag aacccttag agactatgta gaccggttct ataaaactct 1700
aagagcccgag caagcttcac aggaggttaa aaattgagtg acagaaacct tgttgttcca aatgctgac ccagattgta agactatttt aaaaagcattg 1800

                    Gag p24 Capsid end \ / Gag p2 start
ggaccagcgg ctacactaga agaaatgatg acagcatgtc agggagtagg aggaccgggc cataagggcaa gagttttggc tgaagcaatg agccaagtaa 1900

```

Numbering Positions in HIV

```

Gag p2 end \ / Gag p7 Nucleocapsid start
caatlccagc taccataatg atgcagagag gcaatlltag gaaccaaaaga aagattgtta agtgtttcaa ttgtgycaaa gaagggcaca cagccagaana 2000
                                     ribosome -1 slip Gag to Gag-Pol
                                     Gag p7 nucleocapsid end \/\Gag p1 start
                                     pol start >
ttgcagggcc cctaggaaaa agggctgttg gaaatgtgga aaggaagagc accaaatgaa agattgtact gagagacagc ctaatllttt agggaaagatc 2100
                                     Gag p1 end \/\ Gag p6 start
tgcccttcoct acaaggygaag gccaggyaat ttcttcaga gcagaccaga gccaacagcc ccaccagaag agagcttccag gtclyggyta gagacaacaaa 2200
                                     > pol protease start          Gag p6 end <
ctccccctca gaagcagggag ccgatagaca aggaactgta tccttlaact tcctccaggt cactcttgy caacgacccc tcytcacaaat aaagataggy 2300
gggcactaa aggaagctct atlagataca ggaagcagatg atacaglati agaagaatgy aglttggccag gaagatgga accaaaaatg ataggggga 2400
ttggaaggtt tatcaaaagta agacaglatg atcagatact catagaatcc tgtgacata aagctatag tacaglatla gtaagaccct caacctgtcaa 2500
                                     pol protease end \/\ pol p66 and p51 RT start
cataattgga agaaatctgt tgactcagat tggttgcact ttaattttc ccattagccc tattgagact gtaccagtaa aattaagcc aggaatgyat 2600
ggcccaaaag ttaacaatg gccattgaca gaagaaaaaa taaagcatt agtagaat ttgacagaga tgyaaaaaga agggaaaaat tcaaaaatly 2700
ggcctgaaaa tccatcaat actccaatg ttgccataaa gaaaaaagac agtactaat ggaagaat agtagattc agagaactta ataaagaaac 2800
tcaagacttc tgggaagtc aattagaaat accacatccc gcaaggttaa aaaagaanaa atcagtaaca gtactgyatg tgggtgagc atatlltca 2900
gtcccttag atgaaagact caggaaglat actgcattla ccatalcctag lataaacaaat gagaccaccag gvatbagala tcaatcaaat gtccttcac 3000
aggaatggaa aggatccaca gcaatattcc aaagttagcat gacaaaaatc ttaagacctt ttagaacctt ttagaacaa aatccagac atagttatct atcaatacat 3100
gvatgattly tatgtagat ctgacttaga aatagggcag catagaacaa aatagagaga gctyagacaa catctgttga gtyggygact taccacacca 3200
gacaaaaaac atcagaaga accctcattc cttgtagtgy gttatgaact ccattctgat aatygagcag taccgacctat agtyctgcca gaaaaagaca 3300
gctgygactgt caatgacata cagaagttag tggggaatly gaatlygca agtcaagatt acccaggyat laaagtaagy caatlatgta aactcctlag 3400
aggaaccaaa gcactaacag aagtaataacc actaacagaa gaagcagagc tagaactgyc agaaaacaga gagattctaa aagaaaccagt acatgyagty 3500
tattatgacc catcaaaaaga cttaatagca gaaatacaga agcaaggygca agyccaatgy acatlatcaa ttatccaaga gccatlltaa aatctgaaa 3600
caggaaaaata tgcagaagat aggggtgccc acactaatga tgltaaaaaca ttaaccagag cygtgcaaaa aataaccaca gaaagcatalg taatlyggy 3700
aaagactcct aaatlttaac tgcaccataca aaaggaaca tgggaaacat gtygacaga gtattgycaa gccacctgga ttctctgagty gsggttlyt 3800
                                     pol p51 end p66 RT continue \/\ pol p15 RNase H start
aataccccct ccttagtga aattatgylac caglttagaga aagaaccat agtagagca gaaacttct atgtagatgy ggcagctaac agggagacta 3900
aattagyaana agrcagatlat gttactaata gagygaagaca aaaagtlytc accctaacty acacaacaaa tcaagaagact gagttacaag caatllatct 4000
agcttgcag gatccggat tagaaagtaaa catagtaaca gactcaacat atgcatbgy aatcatlcaa gcaacaaccag atcaaaagtya atcaagatla 4100
gtcaatcaaa taatagagca gttataanaa aaggaanaag tctatctgyc atgygtacca gcacacaag gaatlygag aaatgaaaca gtagataaat 4200

```

Numbering Positions in HIV

```

Pol RNase H, p66 RT end \ Pol p31 Integrase start
tagtcaagtc tggatcagc aaggtactat ttttagatgc aatagataag gcccaagatg aacatggaga atatacaagt aattggagag caatggtcag 4300
tgattttaa ctagccacctg tagtagcaaa agaataagta gccagctfgy ataatftrca gctaaaggya gaagccatgc atygacaagt agactgtagt 4400
ccaggaatat gycacaactaga tbtgacacat ttagaaggya aagttatcct ggtagcagtt catgtagcca gtygatbatat agaaagcagaa gttatccag 4500
cagaacacag gcaagyaaca gatatlttc tttaaaat agcagyaaga tggccagtrca aaacaatara tactgacaat gycagcaat tcaccggtgc 4600
tacggttaag gccgcctglt gbtgygcygy aatcaagcag gaatttgya tlccctaca tccccaagt caagyaagtag tagaatctat gaataaagaa 4700
ttaaagaaaa ttataggyca gyttaagagat caggtcgaac atcttaagac agcagtrca atygcaatg tcaatccaaa tttaaaaga aaaaggggya 4800
ttggggggtc cagtrgcagc gaaagaatag tagacataat agccaacagc atacaactaa aagaatara aaaaactat ncaaaaatc aaaaatttcg 4900
ggtttattac aggyacagca gaaatccact ttgyaaagya ccagcaagc tcctctgyaa aggtgaaaggy gcagtragtata tacaagataa tagtgacata 5000

> Vif start
aaagtagtgc caaagaagaaa agccaagatc attagygatt atgyaaaaca gatgyccaggt gatgatgtgy tgyccaagtag acaggatgyag gattagaaca 5100
tgyaaaagtt tagtataaaca ccataatglat gttccaaggya aagctaggygy atggtttat agacatcact atgyaaaagccc tcatccaaga atbaagttcag 5200
aagtracacat cccactaggy gatgctagat tgytaataac aacataatgy ggtctgcata cagyaagaa agactgygcac ttgygtcaggy gactctccat 5300
agaatggaggy aaaaagagat atagcaacaca agtagaccct gaactagcag accaactaat tcatctglat tactttgact gttttcaga ctctgtcata 5400
agaaagycct tattagaca catagtagc ctagtgytg aatataagc aggacataac aagtaggat ctctacaata cttygcacta gcagcattaa 5500

> Vpr start
taacacccaaa aaagataaag ccaaccttgc ctagtgyttac gaactgyaca gaggatagat ggaaccaagcc ccagaagacc aagggccaca gagggagcca 5600

Vif end <
cacaatgaat ggcacactaga gcttttagag gagctlaaga atgaactglt tagacatltt cctagatltt ggtcccatgy ctlaaggyca catatctatg 5700
aaacttatgy ggalacttgy gcagyaagtyg aagccataat aagaatctgy caacaactgc tglttatcca tlttcagaat tgygtgycga catagcagaa 5800

Tat start > Vpr end <
tagggcgttac tgcacagaggy agagcaagaa atgyagccag tagatccctag actagagccc tgyaagcadc cagyaagtca gcctaaaact gcttgytacca 5900

atgctatlyg taaaaagtyt tgccttcatl gccaaagttg tlctacaaca aaagccttag gcatctccta tgyrcagyaag aagcgyagac agcgcagyaag 6000

Rev start >
Tat, Rev exon end \Tat, Rev intron > Vpu start (defective ACG start codon)
agctcatcag aaccagtcaga ctcatcaagc ttctctatca aagcagtaag tagtactaglt aagccaacct ataccatag tagcacaatagt agcattagta 6100
gtagcaataa taatagcaat agttgtyg tccatagtaa tcatagaata tagyaaata ttaagacaaa gaaaataga caggttaatt gatagactaa 6200

> Env gp160 start, signal peptide
tagaaagagc agaagacagt gycaatgaga gtgaagaga aatatcagca cttytgagya tgygggtgyga gatggggcac catgctcctt gggatgttga 6300

```

Numbering Positions in HIV

Vpu end, signal peptide end

```

<
tgatctgtag tgcctacagaa aaattgtggy tcacagctcta ttatgygtrfa cctgttgytgya agygaagcaac caccactcta tttytgcac cagatgctaa 6400
agcatatgat acagaggtlac ataatgtttg ggcacacacat gcctgtgtiac ccacagaccac caaccaccaaa gaagtragtat tgytfaaatgt gacaagaanaat 6500
ttlaacatgt ggaanaatgca catgtglagaa cagatgcatg aggatataat cagttlatgy gatcaaaagcc taagcccatgy tgltaaaalta accccactct 6600
gtgttaagtt aaagtgcata gatlttgyaaga atgatactaa taaccaatagt agttagcygyga gaatgataat gyaagaayga gagaataaaa actgctcttt 6700
caaltatcag acaagcataba gaggtaaagt gcagaagaaga taatgcatttt ttataaaact tgatataata ccaatbagata atgatactac cagctatcag 6800
ttgacaagtt gtaaacacctc agtccattaca caggcctgtc caaagtatrc ctttagacca attcccatac attatltgtgc ccgctgtgt ttgycgataa 6900
taaaatgtaa taataagacy tccaatgyna caggaccatg tacaatgttc agccacgtlac atgtrataca tgyraatlag ccagtagtat caactcaact 7000
gctgttaaat gycagtcttag cagaagaaga ggtagtaalt agatctgtca attcacgyga caatgtrtaaa accataatag tacagctgaa cacatctgta 7100
gaaatlaalt gtaacaagacc caacaacaat acaagaanaaa gaalccglat ccagagaayga ccagygyagay caltgytlac aatagyaanaa atagyaanaa 7200
tgyacaacaagc acattgtlaac attagtlagay caaaatgyaa taaccattta aaacaagatag ctaygcaaat aagyaanaaaa ttgyaanaa ataaacaat 7300
aatctttaag caatccctcag gagggygaccc agaaatgtla acgccaagtt ttaatltgyg aggygaaatt ttctactgta atccaacaa actglttlaat 7400
agttacttgt ttaatagtlac tgyggtact gaaggtcaca ataacactga agyaagtygac acaatcaacc tcccattgag aatbaaacaa atataaaca 7500
tgytgcagaa agtragaanaa gcaatgtatg cccctcccat cagtygacaa attagatgtt catcaaatat tacaggyctg ctalttaacaa gagaatgytgy 7600
taatagcaac aatgyatccg agatcttcag acctgygaya ggaatatgta gggacaaltg gagaagtygaa ttataaata ataaagtagt aaaaattgaa 7700

```

Env gp120 end \ Env gp41 start

```

ccattaggag tagcaaccac caaggycaay agaagatgyg tgcagagayga aaaaagayga gtgygaaatag gagctttgtt ccttgygttc ttgygagcag 7800
caggaagcac tatgygcyca gcctcaatga cyctgacgyt acaggyccaga caatlattgt ctgytatract gcaagcagcag aacaattlgt tgaaggtctat 7900
tgyagcygcaa cagcatctgt tgycaactcac agtctgygyc atcaagcagc tccagycaag aatccitgyct gytgyaaagat acctaaayga tcaacagctc 8000
ctgyggatlt ggygtgtctc tgyaaaactc attgcaacca ctgctgtgcc ttgnaatcct agltgyagta ataatctct gyaacagatt tgyaatcaca 8100
cgacctgyat gyaagtygac agyaanaatla acaaltcacac aagctlaata cactcctkaa ttgaaagatc gcaaaaacag caagyaayga atgyacaaga 8200
atattgygaa ttagataaat ggygaaatlt gtgyaatlgy ttaacataa caaatlgyct gtgytatata aaatlattca laatgtagt aggyaggttg 8300

Tat, Rev intron end \ Tat, Rev exon 2 start
gtagtttaa gaatagttt tgytgtactt tctatagtga atagagtlag gcagygatbat tcaccattat cgtttcagac ccactccca accccgaggy 8400

```

____Tat premature stop

Tat end <

```

gacccgacag gccccaagga atagaagaay aagtygagaa gagagacaga gacagatcca ttcgatragt gaaccgatcc ttgycaactta tctgygacga 8500
tctgcygagc ctgtgcctct tcaagtlacca ccgcttgaga gacttactct tgatltfaac gaggatltgy gaacttctgy gacgyaggyg gtbygaaagcc 8600

Rev end <
ctcaaatatt gtygaaatct cctacaaglat tgyagtcagay aactaaayga tagtgyctgtt agcttgcaca atgcccacagc catagycagta gctgyaggyga 8700

```


Numbering Positions in HIV

```

cagatagggt tatagaagta gtacaaggag ctgttagagc tattcgccac atacctagaa gaataagaca gggcttggaa aggatlttgc tataagatgy 8800
gtggcaagtg gtcaaaaagt agtgygatly gatggcctac tylaaggaa agaatggagc gagctggacc agcagcagat aggttgggag cagcatctcg 8900
agacctggaa aaacatggag caatcaacaag tagcaataca gcagctacca atgctgtly tgcctggcta gaagcaacaag aggaaggagga ggttgggtttt 9000
                                     Env gp41, gp160 end < > Nef start
ccagtcacac ctcaagtlacc tttaagacca atgacttaca aggcagctgt agatctteagc caattlttaa aagaaaaaggg gggactggaa gggctaattc 9100
                                     > 3' LTR U3 region
actcccaanag aagacaagat atccctgatc tgytgatcta ccacacacaa ggctactcc ctgattagca gaactacaca ccagggccag gggtcagata 9200
tccactgacc tttygatgt gctacaagct agtaccaagt gagccaagata agatagaaga ggccaataaa ggaagaaca ccaagctgtt acaccctgtg 9300
agcctgcaty ggaltygatga cccggaaga gaagtgttag agtggaggtt tgacaagccc ctagcatttc atcacytggc ccgaagcty catccggagt 9400
                                     _____ Nef premature stop
Nef end <
acttcaagaa ctgctgacat cgagcttgc tacaaggact ttccgctggg gactttccag ggagggcgtgg cctgggcccgg actggggaggt ggccagccct 9500
cagatcctgc atataagcag ctgctlttly cctgtactgy gtctctctgy ttagaccaga tctgagccty ggagctctct gcttaactag gaaacccact 9600
                                     3' LTR U3 region \ / 3' LTR R repeat
gcttaagcct caataaagct tgccttgagt gttcaagta gtgtgtgtccc gtctgtgtg tgactctgt aactagagat ccctcagacc ctlttagtca 9700
                                     3' LTR R repeat \ / 3' LTR U5 region
3' LTR U5 end <
gtgtggaaaa tctctagca
                                     9719

```

This numbering was based on previous HIV sequence database annotation, cross-checked with protein structure databases, Tozser et al., *FEBS letters* **281**:77–80 (1991), and R. J. Gorelick and L. E. Henderson, *Human Retroviruses and AIDS 1994*, part III, pages 2–10.